Recently, Picroside II and Yangonin were reported to exert protective effects against cholestasis through FXR activation (Gao et al., 2018; Li et al., 2020), and 72 natural compounds were identified as FXR agonists (She et al., 2021). The gene discussed is NR1H4; the disease is cholestasis.